Nanostr.technol. Stock
Nanostr.technol. Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Nanostr.technol. stock is not clear.
Based on the current price of 0.43 € the target price of 4 € shows a potential of 830.23% for Nanostr.technol. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Nanostr.technol. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Nanostr.technol. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Nanostr.technol. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nanostr.technol. | - | - | - | - | - | - | - |
| Orasure Tech | -0.980% | 3.909% | -10.619% | -15.833% | -32.215% | -35.073% | -40.336% |
| scPharmaceuticals | -7.800% | -3.828% | -11.454% | -53.526% | -30.087% | -26.909% | - |
| SI-BONE Inc | -2.140% | -2.837% | 0.000% | -29.744% | -27.895% | -52.431% | - |
Comments
News
NanoString Reports Inducement Grants Under Nasdaq Listing Rules
NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity
NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a
NanoString Comments on Delaware District Court Verdict
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S